Kymera Investor Presentation Deck

KT-333: Phase 1, Multicenter, Dose-Escalation and Expansion Trial to Evaluate KT-333 in Adult Patients with PTCL, CTCL, LGL-L, and Solid Tumors Phase 1b Dose Expansion Opportunities Phase 1a Dose Escalation & MTD/RP2D Expansion (n=~45) Solid Tumor/ Lymphoma DL1 Primary Key Objectives Secondary DL2 Exploratory DL3 LGL- L/T-PLL ● ● ● ● DL4 DL3 KT-333 IV Weekly in 28-day Cycles DL5 DL4 DLX Phase 1a Safety/Tolerability and MTD and RP2D PK Parameters of KT-333 Preliminary Estimates of Activity PD Effects of KT-333 MTD/RP2D Expansion Lymphoma/Solid tumor and LGL- L/T-PLL MTD: Maximum Tolerated Dose. RP2D: Recommended Phase 2 Dose. ORR: Overall Response Rate KYMERA Ⓒ2023 KYMERA THERAPEUTICS, INC. ● ● ● Peripheral T-cell Lymphoma (PTCL) Cutaneous T-cell Lymphoma (CTCL) Large Granular Lymphocytic Leukemia (LGL-L) Advanced Solid Tumors Phase 1b Safety/Tolerability at RP2D in Patients with Lymphoma/Leukemia and Solid Tumors Preliminary Clinical Activity (ORR, DOR, PFS, DCR, OS) PK Parameters of KT-333 PD Effects of KT-333 PAGE 25

View entire presentation